High-Dose Rate Brachytherapy Combined with PD-1 Blockade as a Treatment for Metastatic Adrenocortical Carcinoma – A Single Center Case Series

Abstract

The response rate of advanced adrenocortical carcinoma (ACC) to standard chemotherapy with mitotane and etoposide/doxorubicin/cisplatin (EDP-M) is unsatisfactory, and benefit is frequently short lived. Immune checkpoint inhibitors (CPI) have been examined in patient’s refractory to EDP-M, but objective response rates are only approximately 15%. High-dose rate brachytherapy (HDR-BT) is a catheter-based internal radiotherapy and expected to favorably combine with immunotherapies. Here we describe three cases of patients with advanced ACC who were treated with HDR-BT and the CPI pembrolizumab. None of the tumors were positive for established response markers to CPI. All patients were female, had progressed on EDP-M and received external beam radiation therapy for metastatic ACC. Pembrolizumab was initiated 7 or 23 months after brachytherapy in two cases and prior to brachytherapy in one case. Best response of lesions treated with brachytherapy was complete (n=2) or partial response (n=1) that was ongoing at last follow up after 23, 45 and 4 months, respectively. Considering all sites of tumor, response was complete and partial remission in the two patients with brachytherapy prior to pembrolizumab. The third patient developed progressive disease with severe Cushing’s syndrome and died due to COVID-19. Immune-related adverse events of colitis (grade 3), gastroduodenitis (grade 3), pneumonitis (grade 2) and thyroiditis (grade 1) occurred in the two patients with systemic response. HDR-BT controlled metastases locally. Sequential combination with CPI therapy may enhance an abscopal antitumoral effect in non-irradiated metastases in ACC. Systematic studies are required to confirm this preliminary experience and to understand underlying mechanisms.

Key words

adrenocortical carcinoma, cancer - immune checkpoint blockade - brachytherapy - pembrolizumab - abscopal effect

Publication History

Received: 31 May 2023

Accepted after revision: 02 August 2023

Article published online:
25 September 2023

• References

• 1 Fassnacht M, Terzolo M, Allolio B. et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012; 366: 2189-2197
• 2 Le Tourneau C, Hoimes C, Zarwan C. et al. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer 2018; 6: 111
• 3 Carneiro BA, Konda B, Costa RB. et al. Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial. J Clin Endocrinol Metab 2019; 104: 6193-6200
• 4 Habra MA, Stephen B, Campbell M. et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer 2019; 7: 253
• 5 Raj N, Zheng Y, Kelly V. et al. PD-1 Blockade in advanced adrenocortical carcinoma. J Clin Oncol 2020; 38: 71-80
• 6 Klein O, Senko C, Carlino MS. et al. Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538. Oncoimmunology 2021; 10: 1908771
• 7 Maleki Vareki S, Garrigos C, Duran I.. Biomarkers of response to PD-1/PD-L1 inhibition. Crit Rev Oncol Hematol 2017; 116: 116-124
• 8 Fay AP, Signoretti S, Callea M. et al. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer 2015; 3: 3
• 9 Remde H, Schmidt-Pennington L, Reuter M. et al. Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort study. Eur J Endocrinol 2023; 188: 485-493
• 10 Landwehr LS, Altieri B, Schreiner J. et al. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. J Immunother Cancer. 2020 8.
• 11 Fassnacht M, Assie G, Baudin E. et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31: 1476-1490
• 12 Demaria S, Ng B, Devitt ML. et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004; 58: 862-870
• 13 Mole RH.. Whole body irradiation; radiobiology or medicine?. Br J Radiol 1953; 26: 234-241
• 14 Abuodeh Y, Venkat P, Kim S.. Systematic review of case reports on the abscopal effect. Curr Probl Cancer 2016; 40: 25-37
• 15 Twyman-Saint Victor C, Rech AJ, Maity A. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015; 520: 373-377
• 16 Reijmen E, De Mey S, De Mey W. et al. Fractionated radiation severely reduces the number of CD8+ T cells and mature antigen presenting cells within lung tumors. Int J Radiat Oncol Biol Phys 2021; 111: 272-283
• 17 Megerle F, Kroiss M, Hahner S. et al. Advanced adrenocortical carcinoma – what to do when first-line therapy fails?. Exp Clin Endocrinol Diabetes 2019; 127: 109-116
• 18 Megerle F, Herrmann W, Schloetelburg W. et al. Mitotane monotherapy in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab 2018; 103: 1686-1695
• 19 Fassnacht M, Hahner S, Polat B. et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 2006; 91: 4501-4504
• 20 Khosla D, Kapoor R, Singla AK. et al. Treatment outcomes of adjuvant radiotherapy in adrenocortical carcinoma – a 13-years experience from a tertiary care centre. Rare Tumors 2023; 15 20363613231160699
• 21 Kimpel O, Schindler P, Schmidt-Pennington L. et al. Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma. Br J Cancer 2023; 128: 586-593
• 22 Polat B, Fassnacht M, Pfreundner L. et al. Radiotherapy in adrenocortical carcinoma. Cancer 2009; 115: 2816-2823
• 23 Fassnacht M, Dekkers OM, Else T. et al. European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol 2018; 179: G1-G46
• 24 Grisanti S, Filice A, Basile V. et al. Treatment with 90Y/177Lu-DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors. J Clin Endocrinol Metab 2020; 105
• 25 Lin TY, Lin KY, Kuo HY. et al. Yttrium-90 selective internal radiation therapy plus cryoablation for recurrent adrenocortical carcinoma with liver metastases. J Endocr Soc 2022; 6: bvac091
• 26 Roux C, Boileve A, Faron M. et al. Loco-regional therapies in oligometastatic adrenocortical carcinoma. Cancers (Basel) 2022; 14
• 27 Hannon G, Lesch ML, Gerber SA. Harnessing the immunological effects of radiation to improve immunotherapies in cancer. Int J Mol Sci 2023; 24
• 28 Theelen W, Chen D, Verma V. et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med 2021; 9: 467-475
• 29 Buchwald ZS, Nasti TH, Lee J. et al. Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy. J Immunother Cancer 2020; 8
• 30 Wei J, Montalvo-Ortiz W, Yu L. et al. Sequence of alphaPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses. Sci Immunol 2021; 6
• 31 Young KH, Baird JR, Savage T. et al. Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy. PLoS One 2016; 11: e0157164